Renal Cell Carcinoma (eBook)

Molecular Targets and Clinical Applications

Ronald M. Bukowski, Robert A. Figlin, Robert J. Motzer (Herausgeber)

eBook Download: PDF

2014 | 3rd ed. 2015
XVIII, 613 Seiten
Springer New York (Verlag)
978-1-4939-1622-1 (ISBN)

Infos

​​

​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.

Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​

Ronald M Bukowski MD
Emeritus Staff Physician
Cleveland Clinic Taussig Cancer Center
Professor Emeritus of Medicine
CCF Lerner College of Medicine of CWRU

Robert Figlin MD
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Department of Medicine, Cedars-Sinai Medical Center
Associate Director for Academic Programs
Samuel Oschin Comprehensive Cancer Institute
Professor Emeritus of Medicine and Urology
David Geffen School of Medicine at UCLA

Robert Motzer MD
Attending Physician
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weil Medical College of Cornell University

Inhalt

Table of Contents“Renal Cell Carcinoma: Molecular Targets & Clinical Applications, 3rd Edition”Editors: Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.  Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten YearsRonald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D. Ch. 2: RCC: Pathologic and Molecular assessment of Targets             Ferran Algaba, M.D. Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years            Stephen M. Keefe, M.D., W. Kimryn Rathmell, M.D., Ph.D., Katherine L. Nathanson, M.D. Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications Lucy Gossage, M.R.C.P., M.Sc.  Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling ComplexChung-Han Lee, M.D., Ph.D., Can G. Pham, Ph.D., James J. Hsieh, M.D., Ph.D. Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes Ruhee Dere, Ph.D., Thai H. Ho, M.D., Ph.D. Ch. 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications? Susan A.J. Vaziri, Ph.D, Mahrukh K. Ganapathi, Ph.D, Ram N. Ganapathi, Ph.D. Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results Han Hsi Wong, Ph.D. Tim Eisen, Ph.D., F.R.C.P. Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity? Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,  Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC Bernard Escudier, M.D., Laurence Albiges, M.D. Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC Daniel C. Cho, M.D., James W. Mier, M.D. Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D. Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma Sarathi Kalra, M.D., Eric Jonasch, M.D. Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell CarcinomaFabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D. Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D. Ch. 17: Development of Combination Therapy with Targeted Agents  C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P. Ch. 18: Side Effects of Targeted Thearpy Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D. Ch. 19: The Role of Targeted Therapy in Special Populations James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P. Ch. 20: Immunotherapy: the Current Role of Cytokines Mayer Fishman, M.D., Ph.D. Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC David F. McDermott, M.D., Alexandra Bailey, M.D. Ch. 22: Vaccines in RCC: Clinical and Biological Relevance Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia, Walter J. Storkus, M.D. Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics  Sumanta K. Pal, M.D., Robert A. Figlin, M.D. Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.  Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D.   Ch. 26: The Role of Advocacy in Renal Cell Carcinoma William P. Bro, B.S.B., Paul Larson, M.S.

Produkt-Details

• Erscheint lt. Verlag: 27.11.2014
• Zusatzinfo: XVIII, 613 p. 50 illus., 41 illus. in color.
• Verlagsort: New York
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
• Themenwelt: Medizinische Fachgebiete ► Radiologie / Bildgebende Verfahren ► Nuklearmedizin
• ISBN-10: 1-4939-1622-X / 149391622X
• ISBN-13: 978-1-4939-1622-1 / 9781493916221